GLP-1 drugs like Ozempic linked to rare eye disease risk, study finds
A new study suggests that popular GLP-1 medications — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — may be linked to an increased risk of a rare eye disease that can sometimes cause sudden vision loss. Researchers stress that the overall risk remains small. The drugs are widely prescribed for type 2 diabetes and obesity treatment.
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!